There is currently no DLL1-specific therapy. Care is symptom-directed and follows established pediatric standards. Below is a practical map of what good care typically looks like across six domains.
This page is informational and is not medical advice. The medications and approaches listed are examples of pediatric standards of care — your child's clinical team will choose what is right based on their full picture.
Roughly 4 in 10 children with NEDBAS develop seizures.
Seizure type varies; most respond to standard pediatric anti-seizure medications. Choice of medication should be made by a pediatric neurologist based on the seizure semiology and EEG.
All children with developmental delay or intellectual disability.
Early intervention before age 3 has the strongest evidence base across neurodevelopmental conditions. School-age supports continue under IEPs in the US or EHCPs in the UK.
Children with vertebral findings — required in SCDO7, watchful in NEDBAS.
Recessive SCDO7 carries a high risk of progressive scoliosis and fused ribs/vertebrae. Even children with NEDBAS should have spine examined as part of routine care given reported scoliosis in roughly a quarter of cases.
Infants and children with hypotonia, oral-motor difficulties, or growth concerns.
Feeding therapy and nutrition follow-up address poor weight gain, swallowing safety, and family stress around mealtimes.
Children meeting criteria for ASD or with significant behavioural concerns.
DLL1-related ASD is supported with the same evidence-based interventions used for ASD generally — there is no DLL1-specific behavioural protocol.
Recommended for every child with a confirmed DLL1 diagnosis.
Coordinated care across specialties prevents gaps and reduces the burden on families running their own coordination.